Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans

Background The current strategy for the elimination of onchocerciasis is based on annual or bi-annual mass drug administration with ivermectin. However, due to several limiting factors there is a growing concern that elimination of onchocerciasis cannot be achieved solely through the current strategy. Additional tools are critically needed including a prophylactic vaccine. Presently Ov-103 and Ov-RAL-2 are the most promising vaccine candidates against an Onchocerca volvulus infection. Methodology/Principal findings Protection induced by immunization of mice with the alum-adjuvanted Ov-103 or Ov-RAL-2 vaccines appeared to be antibody dependent since AID-/- mice that could not mount antigen-specific IgG antibody responses were not protected from an Onchocerca volvulus challenge. To determine a possible association between antigen-specific antibody responses and anti-larvae protective immunity in humans, we analyzed the presence of anti-Ov-103 and anti-Ov-RAL-2 cytophilic antibody responses (IgG1 and IgG3) in individuals classified as putatively immune, and in infected individuals who developed concomitant immunity with age. It was determined that 86% of putatively immune individuals and 95% individuals with concomitant immunity had elevated IgG1 and IgG3 responses to Ov-103 and Ov-RAL-2. Based on the elevated chemokine levels associated with protection in the Ov-103 or Ov-RAL-2 immunized mice, the profile of these chemokines was also analyzed in putatively immune and infected individuals; both groups contained significantly higher levels of KC, IP-10, MCP-1 and MIP-1β in comparison to normal human sera. Moreover, human monospecific anti-Ov-103 antibodies but not anti-Ov-RAL-2 significantly inhibited the molting of third-stage larvae (L3) in vitro by 46% in the presence of naïve human neutrophils, while both anti-Ov-103 and anti-Ov-RAL-2 antibodies significantly inhibited the molting by 70–80% when cultured in the presence of naive human monocytes. Interestingly, inhibition of molting by Ov-103 antibodies and monocytes was only in part dependent on contact with the cells, while inhibition of molting with Ov-RAL-2 antibodies was completely dependent on contact with the monocytes. In comparison, significant levels of parasite killing in Ov-103 and Ov-RAL-2 vaccinated mice only occurred when cells enter the parasite microenvironment. Taken together, antibodies to Ov-103 and Ov-RAL-2 and cells are required for protection in mice as well as for the development of immunity in humans. Conclusions/Significance Alum-adjuvanted Ov-103 and Ov-RAL-2 vaccines have the potential of reducing infection and thus morbidity associated with onchocerciasis in humans. The development of cytophilic antibodies, that function in antibody-dependent cellular cytotoxicity, is essential for a successful prophylactic vaccine against this infection.

[1]  M. Theumer,et al.  Helminth Infections: Recognition and Modulation of the Immune Response by Innate Immune Cells , 2018, Front. Immunol..

[2]  A. Wolstenholme,et al.  Human Leukocytes Kill Brugia malayi Microfilariae Independently of DNA-Based Extracellular Trap Release , 2017, PLoS neglected tropical diseases.

[3]  Ashutosh Kumar Singh,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2016, Lancet.

[4]  N. Petrovsky,et al.  The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice , 2016, PLoS neglected tropical diseases.

[5]  P. Hotez,et al.  Vaccination of Gerbils with Bm-103 and Bm-RAL-2 Concurrently or as a Fusion Protein Confers Consistent and Improved Protection against Brugia malayi Infection , 2016, PLoS neglected tropical diseases.

[6]  S. Babayan,et al.  The case for vaccine development in the strategy to eradicate river blindness (onchocerciasis) from Africa , 2015, Expert review of vaccines.

[7]  P. Hotez,et al.  The Onchocerciasis Vaccine for Africa—TOVA—Initiative , 2015, PLoS neglected tropical diseases.

[8]  P. Hotez,et al.  Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model. , 2014, International journal for parasitology.

[9]  T. Nolan,et al.  Extracellular traps are associated with human and mouse neutrophil and macrophage mediated killing of larval Strongyloides stercoralis. , 2014, Microbes and infection.

[10]  P. Hotez,et al.  Elimination and Eradication of Neglected Tropical Diseases with Mass Drug Administrations: A Survey of Experts , 2013, PLoS neglected tropical diseases.

[11]  T. Nutman,et al.  Extended Result Reading Window in Lateral Flow Tests Detecting Exposure to Onchocerca volvulus: A New Technology to Improve Epidemiological Surveillance Tools , 2013, PloS one.

[12]  T. Nolan,et al.  Human and Mouse Macrophages Collaborate with Neutrophils To Kill Larval Strongyloides stercoralis , 2013, Infection and Immunity.

[13]  M. Breloer,et al.  Passive immunization with a monoclonal IgM antibody specific for Strongyloides ratti HSP60 protects mice against challenge infection. , 2012, Vaccine.

[14]  P. Soboslay,et al.  Chemokines and cytokines in patients with an occult Onchocerca volvulus infection. , 2012, Microbes and infection.

[15]  S. Specht,et al.  Granulocytes in Helminth Infection - Who is Calling the Shots? , 2012, Current medicinal chemistry.

[16]  James J. Lee,et al.  Major Basic Protein from Eosinophils and Myeloperoxidase from Neutrophils Are Required for Protective Immunity to Strongyloides stercoralis in Mice , 2011, Infection and Immunity.

[17]  F. Cho-Ngwa,et al.  The Onchocerca volvulus Cysteine Proteinase Inhibitor, Ov-CPI-2, Is a Target of Protective Antibody Response That Increases with Age , 2010, PLoS neglected tropical diseases.

[18]  S. Amini,et al.  Monocyte chemoattractant protein-1 (MCP-1): an overview. , 2009, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[19]  T. Carter,et al.  Mannose-Binding Lectin A-Deficient Mice Have Abrogated Antigen-Specific IgM Responses and Increased Susceptibility to a Nematode Infection1 , 2007, The Journal of Immunology.

[20]  A. Balic,et al.  Cells, cytokines and other molecules associated with rejection of gastrointestinal nematode parasites. , 2005, Veterinary immunology and immunopathology.

[21]  T. Ramalingam,et al.  Critical Role for IgM in Host Protection in Experimental Filarial Infection , 2005, The Journal of Immunology.

[22]  James J. Lee,et al.  Immunoglobulin E and Eosinophil-Dependent Protective Immunity to Larval Onchocerca volvulus in Mice Immunized with Irradiated Larvae , 2004, Infection and Immunity.

[23]  S. Lustigman,et al.  Ov‐ASP‐1, the Onchocerca volvulus homologue of the activation associated secreted protein family is immunostimulatory and can induce protective anti‐larval immunity , 2004, Parasite immunology.

[24]  T. Nolan,et al.  Specificity and Mechanism of Immunoglobulin M (IgM)-and IgG-Dependent Protective Immunity to LarvalStrongyloides stercoralis inMice , 2003, Infection and Immunity.

[25]  S. Lustigman,et al.  CD4+-dependent immunity to Onchocerca volvulus third-stage larvae in humans and the mouse vaccination model: common ground and distinctions. , 2003, International journal for parasitology.

[26]  P. Enyong,et al.  Differential Cytokine and Antibody Responses to Adult and Larval Stages of Onchocerca volvulus Consistent with the Development of Concomitant Immunity , 2002, Infection and Immunity.

[27]  M. Dziejman,et al.  IFN-γ-Inducible Protein 10 (IP-10; CXCL10)-Deficient Mice Reveal a Role for IP-10 in Effector T Cell Generation and Trafficking1 , 2002, The Journal of Immunology.

[28]  V. Titanji,et al.  Expression and characterization of Ov-47, a dominant antigen of Onchocerca volvulus. , 2002, Experimental parasitology.

[29]  E. Pearce,et al.  Immunology of Parasitic Helminth Infections , 2002, Infection and Immunity.

[30]  R. Sandeman,et al.  Antibody‐dependent cell‐mediated cytotoxicity to newly excysted juvenile Fasciola hepatica in vitro is mediated by reactive nitrogen intermediates , 2001, Parasite immunology.

[31]  T. Honjo,et al.  Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme , 2000, Cell.

[32]  P. Enyong,et al.  Immunity to Onchocerciasis: Cells from Putatively Immune Individuals Produce Enhanced Levels of Interleukin-5, Gamma Interferon, and Granulocyte-Macrophage Colony-Stimulating Factor in Response to Onchocerca volvulus Larval and Male Worm Antigens , 2000, Infection and Immunity.

[33]  S. Lustigman,et al.  Characterization of an Onchocerca volvulus L3-specific larval antigen, Ov-ALT-1. , 1998, Molecular and biochemical parasitology.

[34]  A. Luster,et al.  Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation , 1997, Journal of leukocyte biology.

[35]  J. Browne,et al.  Onchocerca volvulus: a comparative study of in vitro neutrophil killing of microfilariae and humoral responses in infected and endemic normals. , 1995, Experimental parasitology.

[36]  D. Taub,et al.  Human Interferon-inducible Protein 10 Is a Potent Inhibitor of Angiogenesis in Vivo , 1995 .

[37]  J. Browne,et al.  Onchocerca volvulus: in vitro cytotoxic effects of human neutrophils and serum on third-stage larvae. , 1994, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.

[38]  L. F. Kolakowski,et al.  The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization. , 1994, The Journal of biological chemistry.

[39]  A. Mantovani,et al.  Chemokines , 1994, The Lancet.

[40]  R. Fernandez-Botran,et al.  Production of soluble IL-4 receptors by murine spleen cells is regulated by T cell activation and IL-4. , 1993, Journal of immunology.

[41]  J. Browne,et al.  Onchocerca volvulus: in vitro killing of microfilaria by neutrophils and eosinophils from experimentally infected chimpanzees. , 1991, Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit.

[42]  A. Hightower,et al.  Guatemalan human onchocerciasis. II. Evidence for IgG3 involvement in acquired immunity to Onchocerca volvulus and identification of possible immune-associated antigens. , 1991, Journal of immunology.

[43]  D. Abraham,et al.  Passive transfer of protective immunity to larval Dirofilaria immitis from dogs to BALB/c mice. , 1991, The Journal of parasitology.

[44]  T. Nutman,et al.  An immunogenic Onchocerca volvulus antigen: a specific and early marker of infection. , 1991, Science.

[45]  A. Prince,et al.  Characterization of an Onchocerca volvulus cDNA clone encoding a genus specific antigen present in infective larvae and adult worms. , 1991, Molecular and biochemical parasitology.

[46]  A. Prince,et al.  Onchocerca volvulus: biochemical and morphological characteristics of the surface of third- and fourth-stage larvae. , 1990, Experimental parasitology.

[47]  D. Friend,et al.  Monoclonal antibodies block murine IL-4 receptor function. , 1990, Journal of immunology.

[48]  Alan I. Alpert,et al.  The murine interleukin-4 receptor: Molecular cloning and characterization of secreted and membrane bound forms , 1989, Cell.

[49]  J. Holy,et al.  Immunity to larval Brugia malayi in BALB/c mice: protective immunity and inhibition of larval development. , 1989, The American journal of tropical medicine and hygiene.

[50]  D. Abraham,et al.  Induction of protective immunity in dogs to infection with Dirofilaria immitis using chemically-abbreviated infections. , 1988, The American journal of tropical medicine and hygiene.

[51]  R. D'antonio,et al.  Litomosoides carinii in jirds (Meriones unguiculatus): ability to retard development of challenge larvae can be transferred with cells and serum , 1984, Journal of Helminthology.

[52]  Brent H. Cochran,et al.  Molecular cloning of gene sequences regulated by platelet-derived growth factor , 1983, Cell.

[53]  N..  "Dipetalonema viteae" (Filarioidea) : evidence for a serum-dependent cytotoxicity against developing third and fourth stage larvae in vitro : short communication , 2019 .

[54]  P. Hotez,et al.  Onchocerca volvulus: The Road from Basic Biology to a Vaccine. , 2018, Trends in parasitology.

[55]  N..  "Dipetalonema viteae" (Filarioidea) : evidence for a serum-dependent cytotoxicity against developing third and fourth stage larvae in vitro : short communication , 2018 .

[56]  Sara Lustigman,et al.  Chapter 67 – Onchocerciasis , 2009 .

[57]  A. Prince,et al.  Identification and characterization of an Onchocerca volvulus cDNA clone encoding a microfilarial surface-associated antigen. , 1992, Molecular and biochemical parasitology.

[58]  A. Capron,et al.  Effector functions of eosinophils in schistosomiasis. , 1992, Memorias do Instituto Oswaldo Cruz.

[59]  D. Weiner,et al.  Protective immune responses of the jird to larval Dipetalonema viteae. , 1986, Immunology.